Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse model of tauopathy

Keyphrases

• Neurodegeneration 100%
• Tauopathy 100%
• Mouse Model 100%
• Sleep Loss 100%
• Lemborexant 100%
• P301S 66%
• Tau Phosphorylation 66%
• Orexin Receptors 66%
• Wild Mice 33%
• Alzheimer's Disease 33%
• Brain Atrophy 33%
• Phosphorylated tau 33%
• Neurodegenerative Diseases 33%
• Induced Damage 33%
• Genetic Ablation 33%
• Therapeutic Potential 33%
• Rapid Eye Movement Sleep 33%
• Receptor Antagonism 33%
• Associated Impairments 33%
• Wakefulness 33%
• Neuroprotective Effect 33%
• Sleep Disturbance 33%
• τ-induced 33%
• Primary tauopathies 33%
• Zolpidem 33%
• Orexin 2 Receptor 33%
• Reactive Microgliosis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Nerve Degeneration 100%
• Tauopathy 100%
• Lemborexant 100%
• Wild Type Mouse 33%
• Alzheimer's Disease 33%
• Degenerative Disease 33%
• Neuroprotective Agent 33%
• Sleep Disorder 33%
• Gliosis 33%
• Brain Atrophy 33%
• Zolpidem 33%
• Orexin Receptor Antagonist 33%
• Orexin Receptor 33%
• Orexin 2 Receptor 33%

Neuroscience

• Neurodegeneration 100%
• Lemborexant 100%
• Tauopathy 100%
• Alzheimer's Disease 33%
• Gliosis 33%
• Neurodegenerative Disorder 33%
• Behavior (Neuroscience) 33%
• Neuroprotective Agent 33%
• Sleep Disorder 33%
• Eye Movement 33%
• Wakefulness 33%
• Orexin Receptor 33%
• Zolpidem 33%
• Orexin 2 Receptor 33%
• Dual Orexin Receptor Antagonist 33%